The ESCMID Study Group for Host and Microbiota Interactions (ESGHAMI) is leading the way in bridging diagnostics, clinical research, and scientific studies across the relatively new field of microbiota research in Europe. The group seeks to understand the clinical significance of host-microbiota associated diseases and health, and explore relevant therapeutic interventions. Their research covers:
ESGHAMI Newsletter, Spring 2024, April 2024
ESGHAMI Newsletter, Spring 2023, April 2023
ESGHAMI Newsletter, Spring 2023, May 2023
ESGHAMI Newsletter, Summer 2023, June 2023
ESGHAMI Newsletter, Summer 2023, September 2023
ESGHAMI Newsletter, Winter 2023, December 2023
Which trial do we need? A sequential multiple assignment randomized trial to determine the optimal Clostridioides difficile treatment sequence.
van Prehn J, van Werkhoven CH, Skinner AM, Guery B, Dubberke ER, Kuijper EJ. Clinical Microbiology and Infection 2024;30(2):165–169.
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection.
van Prehn J, Fitzpatrick F, Kuijper EJ. Lancet Gastroenterol Hepatol. 2022;7(12):1083–1091.
Bacteriophage therapy in humans.
Nir-Paz R, Kuijper EJ. Clin Microbiol Infect. 2023;29(6):679–681.
Update on Microbiota-derived therapies for recurrent Clostridioides difficile infections, 2023.
Benech N, Barbut N, Fitzpatrick F, Krutova M, Davies K, Druart C, Cordaillat-Simmons M, hHeritage J, Guery B, Kuijper E. Clinical Microbiology and Infection. 2023:S1198-743X(23)00597-9.
Faecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma
Update on Live biotherapeutic products and FMT-like treatments for recurrent Clostridioides difficile infections
21 June 2023
Microbiome from benchtop to bedside technical workshop
If you have questions or comments for our study group, we warmly invite you to contact us!